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57 ABSTRACT 
The invention is directed to a method of incorporating 
expanded porphyrins, and particularly of incorporating a 
Sapphyrin or a texaphyrin, before, during, or after chemical 
synthesis of an oligomer to form an expanded porphyrin 
oligonucleotide conjugate, and particularly a sapphyrin- or 
texaphyrin-oligonucleotide conjugate. This method includes 
reacting derivatized nucleotides and a sapphyrin or a texa 
phyrin in a desired order in an automated or manual DNA 
synthesizer having a solid support to form a sapphyrin- or a 
texaphyrin-oligonucleotide conjugate. 
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PHOSPHORAM DITE DERVATIVES OF 
TEXAPHYRNS 
This application is a continuation application of U.S. Ser. 
No. 08/487,722filed Jun. 7, 1995, now U.S. Pat. No. 5,565, 
552, which is a continuation-in-part of U.S. Ser. No. 
08/2310,501, now U.S. Pat. No. 5,567,687, filed Sep. 21, 
1994, and benefit of the filing dates of said earlier filed 
applications are claimed under 35 U.S.C.S120. 
FIELD OF THE INVENTION 
The present invention relates to a method of step-wise 
Synthesis of conjugates of expanded porphyrins and oligo 
nucleotides. 
BACKGROUND OF THE INVENTION 
"Expanded porphyrins” are large, pyrrole-containing 
macrocyclic analogues of the porphyrins. Examples of these 
compounds are porphine, the Smaragdyrins, sapphyrins, 
oxosapphyrins, platyrins, pentaphyrins, hexaphyrins, 
Superphthalocyanines, rubyrins, and texaphyrins. Such mol 
ecules are of potential interest because suitably designed 
systems could act as versatile ligands capable of binding 
larger metal cations and/or stabilizing higher coordination 
geometries than those routinely accommodated within the 
normally tetradentate ca. 2.0 A radius porphyrin core. The 
resulting complexes could have important application in the 
area of heavy metal chelation therapy, serve as contrast 
agents for magnetic resonance imaging (MRI) applications, 
act as vehicles for radioimmunological labeling work, or 
serve as useful photosensitizers for photodynamic therapeu 
tic applications. 
The texaphyrins have been found to be useful as MRI 
contrast agents, as radiation sensitizers and in photodynamic 
therapy (PDT), as well as having the ability to hydrolytically 
cleave phosphate esters, including RNA, and to photolyti 
cally cleave RNA and DNA. Texaphyrin is considered as 
being an aromatic benzannulene containing both 187t- and 
22T-electron delocalization pathways. See, e.g., Sessler, J. 
L. et al., Accounts of Chemical Research, 1994, 27, 43. 
Texaphyrins and water-soluble texaphyrins and method of 
preparation have been described in U.S. Pat. Nos. 4,935.498; 
5,252,720; 5.256399; 5.272,142; and 5.292,414; and in 
international publin.s WO94/29316 and WO95/01996; all of 
which are incorporated herein by reference. 
Sapphyrins and water-soluble sapphyrins and methods of 
preparation having been described in U.S. Pat. Nos. 5,041, 
078; 5.120,411; 5,159,065; and 5,302.714; and in Interna 
tional publin. WO 94/09994; all of which are incorporated 
herein by reference. Rubyrins are described in U.S. Pat. No. 
5,410,045, incorporated herein by reference. 
SUMMARY OF THE INVENTION 
The present invention is directed to a method of incor 
porating expanded porphyrins, and particularly of incorpo 
rating a sapphyrin or a texaphyrin before, during, or after 
chemical synthesis of an oligomer to form a sapphyrin- or 
texaphyrin-oligonucleotide conjugate. This method com 
prises the steps of obtaining an automated or manual DNA 
synthesizer having a solid support. Further steps include 
reacting derivatized oligonucleotides and an expanded 
porphyrin, particularly a Sapphyrin or a texaphyrin, in a 
desired order to form a sapphyrin- or a texaphyrin 
oligonucleotide conjugate. For example, an oligonucleotide 












the solid support. Sapphyrin or texaphyrin may be coupled 
in the final step to form a conjugate with a 5" linkage. 
Alternatively, a sapphyrin or texaphyrin may be coupled to 
the solid support followed by the addition of nucleotides to 
form a conjugate with a 3' linkage. A third possibility is the 
coupling of nucleotides followed by a macrocycle, such as 
texaphyrin or sapphyrin, then followed by nucleotides to 
form a conjugate where an internal residue is a macrocycle. 
The oligonucleotide may be linked to the sapphyrin or 
texaphyrin in a 3' linkage, a 5' linkage, or a linkage internal 
to the oligonucleotide. The texaphyrin or sapphyrin may be 
coupled as a phosphoramidite, H-phosphonate, orphosphate 
triester derivative and may be coupled to the growing end of 
the oligonucleotide in the synthesizer during or in the final 
step of synthesis. 
Following long-standing patentlaw convention, the terms 
'a' and 'an' mean "one or more” when used in this 
application, including the claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the present invention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of specific 
embodiments presented herein. 
FIG. 1A, FIG. 1B, FIG. 1C, FIG. 1D, FIG. 1E, FIG. I.F 
and FIG. 1G show stepwise synthesis schemes for preparing 
texaphyrin metal complex-oligonucleotide conjugates and 
Sapphyrin oligonucleotide conjugates. FIG. 1A shows the 
synthesis of a texaphyrin metal complex 3'-linked 
oligonucleotide conjugate. FIG. 1B and FIG. 1C show an 
approach that results in a 5'-linked oligonucleotide conju 
gate. FIG. 1D shows the synthesis of a 5'-linked sapphyrin 
oligonucleotide conjugate. FIG.1E shows the synthesis of a 
precursor sapphyrin that may be linked to two oligonucle 
otides. FIG. 1F and FIG. 1G show the synthesis of a 
sapphyrin oligonucleotide conjugate via the H-phosphonate 
method. Example 1 provides the details of these stepwise 
synthesis schemes. In FIGS. 1A-1C, M is H, a divalent 
metal cation or a trivalent metal cation; and N will typically 
be an integer less than or equal to 5. In the context of the 
basic macrocycle with a divalent or trivalent metal cation, 
N is 1 or 2; however, the complexes may have one or more 
additional ligands providing charge neutralization and/or 
coordinative saturation to the metalion. 
DETALEED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The present invention provides synthetic procedures in 
which an expanded porphyrin, and in particular a texaphyrin 
or a sapphyrin, is inserted directly into a nucleic acid 
synthesis scheme, preferably on a solid support. Texaphyrin 
and sapphyrin macrocycles were not known to be stable 
under the basic conditions employed in the synthesis of 
oligonucleotides. For example, until the results presented 
herein were obtained, it was thought that texaphyrin, being 
a Schiff base, may be unstable to the basic conditions 
employed during oligonucleotide synthesis, specifically dur 
ing the ammonia and ethanol cleavage and deprotection 
steps. It was also possible that the meso positions of sap 
phyrin would be unstable to the same basic conditions. 
Therefore, the stepwise synthesis of texaphyrin- and 
sapphyrin-oligonucleotide conjugates presented herein was 
a surprising and unexpected result. The synthesis of 
sapphyrin-nucleobase conjugates is described in U.S. Ser. 
5,633,354 
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No. 07/964,607 and International publin. WO 94/09003, 
incorporated by reference herein. 
It is contemplated that the stepwise synthesis provided 
herein may be performed manually or may be automated, 
and may be in a solution-phase or on a solid support. Solid 
Support synthesis may be accomplished using an automated 
or a manual nucleic acid synthesizer. Common solid Sup 
ports are CPG (control pore glass) and CPS (control pore 
silica). Other possible solid supports include polystyrene, 
polyamide/Kieselguhr, and cellulose paper. A preferred 
embodiment of this method is automated synthesis on a solid 
Support. 
Attachment of a texaphyrin or sapphyrinto an oligonucle 
otide during stepwise synthesis obviates the need for a 
postmodification protocol and a second purification of the 
product. This results in an improved yield and greatly 
facilitates scale-up. The texaphyrin may be a free base 
texaphyrin or may be a texaphyrin metal complex. 
Oligomeric DNA, up to ca 100 residues in length, can be 
prepared on a commercial synthesizer, such as for example 
Applied Biosystems Inc. model 392. Most commercial syn 
thesizers employ phosphoramidite chemistry. In brief, DNA 
is synthesized from the 3' to the 5' direction through the 
sequential addition of highly reactive phosphorus(III) 
reagents called phosphoramidites. The initial 3' residue is 
covalently attached to a controlled porosity silica solid 
Support, which greatly facilitates manipulation of the poly 
mer. After each residue is coupled to the growing polymer 
chain, the phosphorus(DT) is oxidized to the more stable 
phosphorus(V) state by a short treatment with iodine solu 
tion. Unreacted residues are capped with acetic anhydride, 
the 5'-protective groups is removed with weak acid, and the 
cycle may be repeated to add another residue. The full 
length polymer is released from the solid support, with 
concommitant removal of remaining protective groups, by 
exposure to base: A common protocol uses saturated etha 
nolic ammonia. 
The finding that lanthanide(III) metal complexes of 
texaphyrins, notably DyT2B2 (cpd. 1, M=Dy) and EuT2B1 
(cpd. 1, M=Eu), are stable to treatment with ethanolic 
ammonia for 24 h at ambient temperature suggests that it is 
possible to derivatize oligomers with lanthanide(III) texa 
phyrin complexes during stepwise synthesis to produce 















A texaphyrin or metal complex thereof or a sapphyrin 
molecule may be inserted into the synthesis scheme of an 
oligonucleotide in a variety of ways. Possible linkages 
include aide, phosphate, thioether, amino, and ether link 
ages. An amide linkage represents the reaction of an acti 
vated carboxylic acid derivative of a macrocycle (such as 
cpd. 1) and an amino linker attached to an oligonucleotide. 
Activation may be achieved in solution phase or on a solid 
support using DCC and NHS, EDC, or activated esters of 
NHS, nitrophenyl, pentachlorophenyl, acid anhydride, or 
sulfonyl chloride. In addition, for the solid support reaction, 
activation may be in the form of an acid chloride. A 
phosphate linkage represents the reaction of an activated 
phosphate derivative of a macrocycle and the 5’ hydroxyl 
group on an oligonucleotide. The activated phosphate may 
be a phosphoramidite, an H-phosphonate, a triester, or a 
diester. 
The terms "expanded porphyrin-oligonucleotide 
conjugate", "sapphyrin-oligonucleotide conjugate' and 
"texaphyrin-oligonucleotide conjugate” mean that a nucle 
otide or an oligonucleotide is attached to the expanded 
porphyrin, sapphyrin or texaphyrin, respectively, in a 5" or a 
3' linkage, or in both types of linkages to allow the macro 
cycle to be an internal residue in the conjugate. It can also 
refer to an expanded porphyrin, a sapphyrin or a texaphyrin, 
respectively, that is linked to an internal base of the nucle 
otide or oligonucleotide. The nucleotide or oligonucleotide 
may be attached either directly to the expanded porphyrin, 
sapphyrin or texaphyrin or to the macrocycle via a linker or 
a couple of variable length. 
It is understood that the terms "nucleotide", "polynucle 
otide” and "oligonucleotide", as used herein and in the 
appended claims, refer to both naturally-occurring and syn 
thetic nucleotides, poly- and oligonucleotides and to analogs 
and derivatives thereof such as methylphosphonates, 
phosphotriesters, phosphorothioates and phosphoramidates 
and the like. Deoxyribonucleotides, deoxyribonucleotide 
analogs and ribonucleotide analogs are contemplated as 
being useful in the present invention. 
The nucleotides or oligonucleotides may be derivatized at 
the bases, the Sugars, the ends of the chains, or at the 
phosphate groups of the backbone to promote in vivo 
stability. Modifications of the phosphate groups are pre 
ferred in one embodiment since phosphate linkages are 
sensitive to nuclease activity. Presently preferred oligo 
nucleotide derivatives are the methylphosphonates, 
phosphotriesters, phosphorothioates, and phosphoramidates. 
Additionally, the phosphate linkages may be completely 
substituted with non-phosphate linkages such as amide 
linkages. Appendages to the ends of the oligonucleotide 
chains also provide exonuclease resistance. Sugar modifi 
cations may include groups, such as halo, alkyl, alkenyl or 
alkoxy groups, attached to an oxygen of a ribose moiety in 
a ribonucleotide. In a preferred embodiment, the group will 
be attached to the 2' oxygen of the ribose. In particular, 
halogen moieties such as fluoro may be used. The alkoxy 
group may be methoxy, ethoxy or propoxy. The alkenyl 
group is preferably allyl. The alkyl group is preferably a 
methyl group and the methyl group is attached to the 2' 





Representatives of texaphyrins which may be activated 
and attached to nucleotides following the present invention 
are included within the following structure I: 
wherein, M is H, a divalent metal cation or a trivalent metal 
cation; R-R, R and Rs are independently hydrogen, 
halide, hydroxyl, alkyl, aryl, haloalkyl, nitro, formyl, acyl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, saccharide, 
carboxy, carboxyalkyl, carboxyamide, carboxyamidealkyl, 
aminoalkyl, sulfonatoalkyl, amidealkyl, or aryl; R and R. 
are independently selected from the groups of R-R,R, and 
Rs, with the proviso that the halide is other than iodide and 
the haloalkyl is other than iodoalkyl; Rs and Ro-R2 are 
independently hydrogen, alkyl, aryl, hydroxyalkyl, 
oxyalkyl, oxyhydroxyalkyl, carboxyalkyl, or carboxyamid 
ealkyl; and Zwill typically be an integer less than or equal 
to 5. 
Representatives of sapphyrins which may be activated 
and attached to nucleotides following the present invention 
are disclosed in International publin. WO 94/09003, the 
disclosure of which is incorporated herein by reference. 
The following example discusses four representative syn 
thetic schemes. 
EXAMPLE 1. 
Stepwise Synthesis of Texaphyrin- and Sapphyrin 
Oligonucleotide Conjugates 
In the approach depicted in FIG. 1A; a meta-texaphyrin 
("txp”) complex 7A is attached to a solid support 7A via 
a six-carbon amine linker. This amide-forming coupling 
reaction is currently employed to attach the complex post 
synthetically. It is important to note that texaphyrin hydroxyl 
groups are protected as an ester on 7A for stepwise syn 
thesis. These protecting groups are labile to the ethanolic 
ammonia treatment. Such a metal-txp-derivatized support 
may be used for stepwise synthesis, and upon cleavage and 
deprotection, results in a 3'-linked metal-txp-DNA conjugate 
7A. The amide-forming reaction may also occur at the 
conclusion of DNA synthesis before deprotection and cleav 
age from the solid support. 
As depicted in FIG. 1B, a phosphoramidite derivative of 
a metal texaphyrin complex 7B is prepared by reaction of 
the monoalcohol 7B 1 with phosphitylating agent and diso 
propylethylamine. The hydroxyl groups are again protected 
as the ester for this synthesis. The resulting phosphoramidite 
is coupled on the synthesizer as the final residue toform7B3. 
In this approach, deprotection results in a 5'-linked txp-metal 
complex-DNA conjugate 7C2. This txp-conjugate has no 
amide bonds in the linker. 
Atxp-DNA conjugate having the texaphyrin in an internal 













stepwise approach. A dihydroxytexaphyrin is treated with 
dimethoxytrityl chloride in the presence of dimethylami 
nopyridine and pyridine. The resulting monoprotected texa 
phyrin is treated with phosphitylating agent and diisopro 
pylethylamine to produce a monoprotected 
phosphoramidite. This product is coupled to a growing 
oligonucleotide during synthesis in place of a nucleotide 
residue to insert a texaphyrin in an internal linkage. The 
monoconjugate may then be further coupled to nucleotides 
to produce atxp-DNA conjugate having the texaphyrin in an 
internal linkage to the oligonucleotide. Additionally, phos 
phonate orphosphodiester derivatives of texaphyrin may be 
utilized to form similar internal, 3', or 5" linkages by the 
phosphonate or triester methods, respectively. 
Oligonucleotide analog conjugates may be coupled to 
texaphyrins in a similar manner as herein described. In 
particular, phosphorothioates, 2'-O-methylated 
ribonucleotides, or other nucleic acid analogs such as methyl 
phosphonate derivatives are preferred due to the enhanced 
stability the derivatization provides towards nucleases in 
WVO. 
Other macrocycles may be coupled to oligomers to form 
macrocycle-nucleic acid conjugates in a similar manner. For 
example, sapphyrin-oligonucleotide conjugates have been 
made using a direct coupling amide linkage method or by 
incorporation during oligonucleotide synthesis forming a 5' 
linkage via the H-phosphonate method as follows. Direct 
coupling method (amide linkage): Sapphyrin 
oligonucleotide conjugates with an amide linkage were 
formed on a solid support (FIG. 1D). Specifically, sapphyrin 
monoacid 7 D (6.8 mg, 0.011 mmol, 50 eq) was dissolved 
in 2 mL of methylene chloride in a 4 mill glass vial with a 
small stirbar followed by cooling to 0°C. with an ice bath. 
Dicyclohexylcarbodiimide (4.5 mg, 0.022 mmol, 100 eq), 
dimethylaminopyridine (0.001 mg. catalytic amount), and 
N-hydroxysuccinimide (2.5 mg, 0.022 eq, 100 eq) were 
added to the solution which was then stirred for 30 min. 
Protected amino-derivatized oligonucleotide attached to 
CPG solid support (7D 2.5 mg, 0.108 Mol, 1 eq) was 
added to the solution which was stirred overnight at room 
temperature. The solution was filtered, and the conjugate 
attached to the CPG (7D) was washed once with methylene 
chloride and twice with methanol. The green solids were 
then suspended in conc. ammonium hydroxide for 4 h at 
room temperature after which the green solution was filtered 
and evaporated to afford the crude sapphyrin 
oligonucleotide conjugate 7D4. The conjugate 7D could be 
purified by fplc on a Cs column using acetonitrile/100 mM 
triethylammonium acetate, pH 7.0. 
This method is similar to that described to form 
texaphyrin-oligonucleotide conjugates. The coupling step in 
this case was done on a solid support although it may be 
done in solution. This procedure attaches sapphyrinto the 5' 
end of the oligonucleotide and could be modified to link 
macrocycles to the 3' end, or internal to an oligonucleotide. 
Incorporation during oligonucleotide synthesis 
(phosphate linkage): The monoprotected sapphyrin 
H-phosphonate 7F (7E) was synthesized for incorporation 
during oligonucleotide synthesis (FIG. 1E). A sapphyrin 
conjugate 7G was synthesized in a solid-phase manual 
oligonucleotide synthesizer via the H-phosphonate method 
(FIG. 1F and FIG. 1G). The oligonucleotide was assembled 
on a solid support such as controlled pore glass (CPG) by a 
cycle of steps. The 5' end of the growing oligonucleotide 
was deprotected, the reaction phase was neutralized, and the 
activated monoprotected nucleotide H-phosphonate was 




sapphyrin 7F (7E) was incorporated at the 5' end of the 
oligonucleotide 7F during the last step of the synthesis in 
place of a nucleotide (FIG. 1F). 
Specifically, the desired oligonucleotide was synthesized 
on a CPG solid support on a 0.2M scale. The derivatized 
sapphyrin 7F (7E) was attached to the oligonucleotide 7F 
on a manual oligonucleotide synthesizer (Cruachem. PS 150 
DNA Synthesizer, Sterling, Va.). The synthesis was run 
under argon (5 psi). Syringes were oven-dried and kept in a 
desiccator until use. The following sequence was used for 
coupling: 
1. Wash-acetonitrile-2 min. 
2. Deblock-3% dichloroacetic acid in methylene 
chloride-3 min. 
3. Wash-acetonitrile-2 min. 
4. Wash-acetonitrile/pyridine (1:1)-2 min. 
5. Couple-4 mM derivatized sapphyrin 7F (7E) (1 eq) 
in methylene chloride and 65 mM pivaloyl chloride in 
acetonitrile/methylene chloride (1:1)-30 L solution 
alternating for 1.5 min. 
6. Wait-15 min. 
7. Wash-acetonitrile, acetonitrile/pyridine (1:1), 
acetonitrile-2 min, 1 min, 2 min. 
8. Deprotect-3% dichloroacetic acid in methylene 
chloride-3 min. 
9. Wash-acetonitrile, acetonitrile/pyridine (1:1)-2 min, 
2 min. 
10. Oxidize-0.1M iodine in water/pyridine/N- 
methylimidazole/THF (5/4/1/90), 0.1M iodine in 
water?triethylamine/THF (5/5/90)-2 min, 2 min. 
11. Wash-acetonitrile/pyridine (1:1), acetonitrile, 
methanol-2 min, 1 min, 2 min. 
The conjugate 7P attached to CPG was added to 2 mL 
conc. ammonium hydroxide for 4 h. The solution was 
filtered and the filtrate was evaporated to afford crude 
sapphyrin-oligonucleotide conjugate 7G1 which could be 
purified by fplc on a C column using acetonitrile/100 mM 
triethylammonium acetate pH 7.0. 
This method may be used to synthesize any type or length 
of oligonucleotide with macrocycle modifications at the 5' 
end or in the interior of the oligonucleotide. Additionally, the 
oligonucleotide could be modified with multiple macro 
cycles. 
A further method for the synthesis of macrocycle 
oligonucleotide conjugates is to incorporate nucleotides 
enzymatically. A variety of DNA and RNA polymerases may 
be used; however, the Klenow fragment of DNA polymerase 
Ifrom E. coli and terminal deoxynucleotidyltransferase are 
preferred. Goodchild, J. (1990) provides a general discus 
sion of the enzymatic synthesis of, oligonucleotides and is 
incorporated by reference herein. 
EXAMPLE 2 
Preparation of a Texaphyrin Phosphoramidite 
A texaphyrin phosphoramidite compound for use in cou 
pling to a nucleotide according to the method of the present 
invention was prepared as follows. 
1,2-Dinitro-4-hydroxy-5-methoxybenzene. Dinitrovera 
trole (5 g, 0.0219 mol) was dissolved in glacial acetic acid 
(50 mL), and concentrated HBr (48% w/win water, 165 mL) 
was added all at once at room temperature (RT). The 
reaction temperature was elevated to 110° C., and the system 













was added and a mixture of starting material and target was 
extracted from the aqueous phase using chloroform (2x400 
mL). Target material was extracted from the chloroform 
layer using 2N sodium hydroxide solution (600 mL). The 
basic aqueous phase was washed with chloroform (2x200 
mL) to remove remaining traces of starting material. The 
organic layers from the basic extractions were combined and 
dried over anhydrous magnesium sulfate. Removal of sol 
vents under reduced pressure resulted in recovered starting 
material as a bright crystalline solid (2.35 g). The basic 
aqueous extract was acidified to pHK1 using conc. HCl (37 
mL) and extracted with ethyl acetate (2x250 mL). The 
organic extracts were combined and dried over anhydrous 
magnesium sulfate. Solvents were removed under reduced 
pressure to yield the title compound as a yellow, powdery 
solid (1.82 g). 
1,2-Dinitro-4-(1-hydroxyhexyl)oxy-5-methoxybenzene. 
To a solution of the methoxybenzene prepared above (270 
mg, 1.259 mmol) in acetonitrile (40 mL) was added 
6-bromo-1-hexanol (330 L, 2.519 mmol), followed by 
sodium iodide (190 mg, 1.259 mmol) and potassium car 
bonate (697 mg, 5.045 mmol). The reaction was heated at 
70° C. under a nitrogen atmosphere. After 5 days, the 
reaction mixture was cooled to 0° C. and filtered through a 
fine sintered glass funnel. Solvents were removed under 
reduced pressure and the resulting solid was dissolved in 
isopropyl alcohol (2 mL). The target product was precipi 
tated by the addition of hexane (20 mL) to the rapidly stirred 
solution. The solid was filtered, washed with hexane and 
dried under reduced pressure to yield the crude target as a 
bright yellow solid (344 mg). Purification by short-bed silica 
gel chromatography using methylene chloride as the mobile 
phase resulted in the isolation of the product as a pale yellow 
crystalline solid (274 mg, 69%). 
4-(1-Hydroxy hexyl)oxy-5-methoxy-1,2- 
phenylenediamine. 1,2-Dinitro-4-(1-hydroxyhexyl)oxy-5- 
methoxybenzene (300 mg, 0.9546 mmol) was dissolved in 
methanol (30 mL). Conc, HCl (1 mL) was added, followed 
by palladium catalyst (10% on activated carbon, 90mg). The 
reaction was shaken under a hydrogen atmosphere at 45 psi. 
After 5 h, when the uptake of hydrogen was complete, the 
catalyst was removed by filtration over celite. Solvent was 
removed under reduced pressure to yield the target com 
pound as the dihydrochloride salt (305 mg, 98%). 
4,5,9.24-Tetraethyl-16(1-hydroxyhexyl)oxy-17 
methoxypentaazapentacyclo[20.2.1.1.1'.0''' 
heptacosa- 1,3,5,7,9,11(27), 12,14,16,18,20,22(25),23 
tridecaene. To a solution of the above 
phenylenediamine.2HCl (485 mg, 1.4821 mmol) in metha 
noi (240 mL) was added solid 2,5-bis(5-formyl-3-ethyl-4- 
methylpyrrol-2-yl)methyl-3,4-diethylpyrrole in one go, 
under a nitrogen atmosphere. After heating at 75° C. for 2 h, 
the reaction was allowed to cool to RT. charcoal (330 mg) 
was added to the solution and the system was stirred for 15 
min. The charcoal was removed by filtration over celite, and 
the solvent was removed under reduced pressure. The target 
compound was isolated as the dihydrochloride salt in the 
form of an orange glass (900 mg, 85%). 
Dysprosium complex of 4.5.9.24-tetraethyl-16(1- 
hydroxyhexyl)oxy-17-methoxy-pentaazapentacyclo 
(20.2.1.1.1.0', heptacosa-1,3,5,7,9,11(27),12,14, 
16, 1820,22(25).23-tridecaene, cpd. 2. To a solution of the 
tridecaene prepared above (130mg, 0.1824 mmol) in metha 
nol (30 mL) was added dysprosium nitrate pentahydrate 
(120 mg, 0.2736 mmol), followed by triethylamine (260 pil, 
1.834 mmol). The reaction was heated under gentle reflux 
open to the air. After 2.5 h, the reaction was allowed to cool 
5,633,354 
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to RT and was filtered through a pad of celite. Solvent was 
removed under reduced pressure and the resulting crude 
complex was triturated in acetone (30 mL) for 10 min. The 
solid was isolated by suction filtration and dried under 
reduced pressure. To remove unbound dysprosium metal 
ion, the complex was dissolved in a mixture of methanol/ 
water (9:1, 15 mL) and gently agitated with zeolite (SAY-54, 
600mg), which had been previously rinsed with dilute HCl 
and deionized water. After 1.5h, the Zeolite was removed by 
filtration and the process was repeated using fresh Zeolite. 
After removal of the zeolite, n-butyl alcohol (10 mL) was 
added to the system to prevent bumping during solvent 
removal. Solvents were removed under reduced pressure to 
yield the target compound 2 as the dinitrate salt in the form 
of a deep green solid (97 mg, 58%). MS (FABLR) 
M-HNO-NO 796. 
Dysprosium complex of 2-cyanoethyl-N,N-diisopropyl 
6-(45.9.24-tetraethyl-17-methoxy-pentaazapentacyclo 
(20.2.1.1.1.0'-heptacosa-1,3,5,7,9,11(27), 12.14, 
16, 18, 20, 22(25), 23-tride caene - 16 (1 - oxy) 
hexylphosphoramidite, cpd. 2. To the solid Dy complex 
prepared above (104 mg., 0.1129 mmol) under a strict 
nitrogen atmosphere was added anhydrous dichloromethane 
(4 mL) followed by N,N-diisopropylethylamine (79 L, 





L, 0.3386 mmol) was added via syringe. After 3.5 h, the 
reaction was quenched using anhydrous methanol (416 L), 
and diluted using methylene chloride (8 mL). The solution 
was washed with saturated sodium bicarbonate (12 mL), 
followed by saturated sodium chloride (10 mL). The organic 
layer was concentrated to a volume of approximately 2 mL 
and added dropwise to vigorously stirring diethyl ether (46 
mL). The resulting solid was isolated by centrifugation 
(2000 rpm, 5 min.) and washed with diethyl ether (3x46 
mL), isolating the solid after each wash by centrifugation. 
Solvents were removed under reduced pressure to yield the 
title compound 2 as a deep green solid (80 mg). 
O(CH2)6OH 
(NCCHCHOGPNPC 
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EXAMPLE 3 
Preparation of a Dual Texaphyrin Phosphoramidite 
Following the procedures of Example 2, a dual texaphyrin 
phosphoramidite 3 may be prepared from the DyTx com 




Such a dual texaphyrin phosphoramidite is useful in 
preparing a texaphyrin-oligonucleotide conjugate having 
two texaphyrin macrocycles at the terminus of the 
oligonucleotide, which conjugate would be expected to have 
greater hydrolytic or photolytic cleavage activity of an RNA 
or DNA, for example. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the composition, methods, and in the steps or in 
the sequence of steps of the method described herein without 
departing from the concept, spirit, and scope of the inven 
tion. More specifically, it will be apparent that certain agents 
which are both chemically and physiologically related may 
be substituted for the agents described herein while the same 
or similar results would be achieved. All such similar 
substitutes and modifications apparent to those skilled in the 
art are deemed to be within the spirit, scope, and concept of 
the invention as defined by the appended claims. 
What is claimed is: 
1. A phosphoramidite derivative of a texaphyrin metal 
complex. 
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2. A phosphoramidite derivative of a texaphyrin metal 





M is a divalent metal cation or a trivalent metal cation; 
R-R, R and Rs are independently hydrogen, halide, 
hydroxyl, alkyl, aryl, haloalkyl, nitro, formyl, acyl, 






carboxy, carboxyalkyl, carboxyamide, 
carboxyamidealkyl, aminoalkyl, sulfonatoalkyl, 
amidealkyl, aryl, aralkyl, phosphoramidityl, 
alkylphosphoramidityl, or alkoxyphosphoramidityl, 
with the proviso that one of R-R, R and Rs is 
phosphoramidityl, alkylphosphoramidity, or alkoxy 
phosphoramidityl; 
RandR are independently selected from the groups of 
R-R, R and Rs, with the proviso that the halide is 
other than iodide and the haloalkyl is other than 
iodoalkyl; 
Rs and Ro-R2 are independently hydrogen, alkyl, aryl, 
hydroxyalkyl, oxyalkyl, oxyhydroxyalkyl, 
carboxyalkyl, or carboxyamidealkyl; and 
Z is an integer less than or equal to 5. 
3. Aphosphoramidite derivative of a texaphyrin according 
to claim 2 wherein R is alkyl or hydroxyalkyl; R2 R3 and 
Rare alkyl; R. R. and RR are hydrogen; and one of R7 
and Rs is phosphoramidityl, alkylphosphoramidityl, or 
alkoxyphosphoramidityl. 
4. Aphosphoramidite derivative of a texaphyrin according 
to claim 2 wherein R is CHCH or CHCH2CH2OH.; R2 
and R are CH2CH; R is CH3; Rs, R., and R-R-2 are H; 
R is H, OCH or O(CHCHO)CHCHOCH; and Rs is 
alkoxyphosphoramidityl where the alkoxy has from one to 
ten carbon atoms. 
5. Aphosphoramidite derivative of a texaphyrin according 
to claim 4 wherein Rs is alkoxyphosphoramidityl where the 
alkoxy has from three to six carbon atoms. 
6. Aphosphoramidite derivative of a texaphyrin according 
to claim 4 wherein Rs is 3-B-cyanoethyl-N,N-bis 
(diisopropyl)phosphoramiditylpropoxy or 6-3- 
cy a no ethyl-N,N- b is ( di is op ropyl) 
phosphoramiditylhexanoxy. 
7. Aphosphoramidite derivative of a texaphyrin according 
to claim 2 wherein M is selected from the group consisting 
of Y(III), Mn(II), Mn(III), Fe(II), Fe(III), and the lanthanide 
metals. 
8. Aphosphoramidite derivative of a texaphyrin according 
to claim 2 wherein M is selected from the group consisting 
of Gd(III), Dy(III), Eu(III), La(III), Lu(III), Tb(ITI), and 
Y(III). 
9. Aphosphoramidite derivative of a texaphyrin according 
to claim 3 wherein M is selected from the group consisting 









10. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 3 wherein M is selected from the group 
consisting of Gd(III), Dy(III), Eu(III), La(III), Lu(III), 
Tb(III), and Y(III). 
11. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 4 wherein M is selected from the group 
consisting of Y(III), Mn(II), Mn(III), Fe(II), Fe(III), and the 
lanthanide metals. 
12. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 4 wherein M is selected from the group 
consisting of Gd(III), Dy(III), Eu(III), La(III), Lu(III), 
Tb(III), and Y(III). 
13. A phosphoramidite derivative of a texaphyrin metal 
complex, said derivative having the following formula: 
wherein, M is a divalent metal cation or a trivalent metal 
cation, and n is an integer from 1 to 10. 
14. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 13 wherein n is an integer from 3 to 6, and M 
is selected from the group consisting of Y(III), Mn(II), 
Mn(III), Fe(II), Fe(III), and the lanthanide metals. 
15. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 13 wherei. n is 3 or 6, and M is selected from 
the group consisting of Gd(III), Dy(III), Eu(III), La(III), 
Lu(III), Tb(III) and Y(III). 
16. A phosphoramidite derivative of a texaphyrin metal 






wherein, M is a divalent metal cation or a trivalent metal 
cation, BZ is a protecting group, and n is an integer from 1 
to 10. 
17. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 16 wherein n is an integer from 3 to 6, and M 
is selected from the group consisting of Y(III), Mn(II), 
Mn(III), Fe(II), Fe(III), and the lanthanide metals. 
25 
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18. A phosphoramidite derivative of a texaphyrin accord 
ing to claim 16 wherein n is 3 or 6, and M is selected from 
the group consisting of Gd(III), Dy(III), Eu(III), La(III), 
Lu(EII), Tb(III) and Y(III). 
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